Holdings
Defilade Capital Management, L.P.
As of Sep 30, 2026, Defilade Capital Management, L.P. reported 28 positions worth US$550M. Largest: Pfizer, Inc., Eli Lilly and Company and BioMarin Pharmaceutical Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Pfizer, Inc. | 1.52M | US$43.5M | −247K | Sep 30, 2026 |
| Eli Lilly and Company | 34,774 | US$40.2M | −4,312 | Sep 30, 2026 |
| BioMarin Pharmaceutical Inc. | 602K | US$36.1M | −80,083 | Sep 30, 2026 |
| Gilead Sciences, Inc. | 227K | US$33.8M | new | Sep 30, 2026 |
| Axsome Therapeutics, Inc. | 175K | US$32.3M | new | Sep 30, 2026 |
| Amgen Inc. | 74,079 | US$31.2M | new | Sep 30, 2026 |
| ORIC Pharmaceuticals, Inc. | 2.27M | US$30.6M | +1.22M | Sep 30, 2026 |
| Intuitive Surgical, Inc. | 71,860 | US$29.2M | new | Sep 30, 2026 |
| Stryker Corporation | 81,524 | US$22.5M | new | Sep 30, 2026 |
| Vera Therapeutics, Inc. | 652K | US$21.1M | new | Sep 30, 2026 |